SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Kramer who wrote (1065)5/7/2000 10:20:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 52153
 
The issue with Salmonella, E. coli, Listeria, etc. has always been margins. It is easy to come up with a rapid diagnostic. If you don't have reagents and associated instrumentation, you're likely to work very hard for almost nada.

Tell us about margins -- what they are and how they'll be maintained. These are not new concepts, and this is the six year chart characteristic of a company that is doing solid work on low-margin projects.......

quote.yahoo.com



To: Kramer who wrote (1065)5/7/2000 10:22:00 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Kramer -

I would guess that on e coli at least the Igen test is already past the neog test. The analysis I saw showed it about two orders of magnitude more sensitive than standard e coli tests, which translates into quicker results, as you don't have to let things incubate as long.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News